Japan: Summary Of IP High Court Grand Panel Decision On Scope Of Patent Right With Registered Patent Term Extension

Last Updated: 15 March 2017
Article by Masaru Nakajima

ABSTRACT

The Intellectual Property High Court (IP High Court) handed down a decision on January 20, 2017, in the 11th Grand Panel case in total, i.e., Appeal Case No. 2016 (ne) 10046, in which injunction against patent infringement was sought. The issue of contention was how to determine the effective scope of a patent right the term of which was extended via patent term extension (PTE) registration based on marketing approval of a pharmaceutical product (administrative deposition). In the decision, the IP High Court ruled that the effective scope of a patent right extended via PTE registration shall not be limited to a product identical to the subject of the deposition on which the PTE registration of the patent is based, but shall extend to a product which is substantially identical to the subject of the deposition. The court also ruled that if there is a difference from the subject of the deposition, the allegedly infringing product shall be deemed to be substantially identical to the deposition subject and thereby fall within the effective scope of the patent right extended via PTE registration, provided that the difference is deemed merely a minor difference or a formal difference as a whole.

1. PTE System in Japan:

The Patent Term Extension (hereinafter "PTE") system prescribed in Japan Patent Law is intended to address a situation where there is a period during which a patented invention cannot be worked due to it being necessary to obtain an administrative disposition designated by Cabinet Order. In other words, the PTE system provides compensation for a period lost in order to obtain a disposition by allowing the duration of the patent right (or "patent term") to be extended for up to five years (Article 67, paragraph 2 of the Patent Law).

The dispositions designated by Cabinet Order prescribed in Article 67, paragraph 2 of the Patent Law1 include:

  1. registration of agrochemicals under the Agricultural Chemicals Regulation Act; and
  2. marketing approval and registration of pharmaceuticals, in-vitro diagnostics, and regenerative medical products (also referred to as "pharmaceutical drugs, etc." or simply as "drugs") under the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (also referred to simply as "the Pharmaceutical and Medical Device Act")2.

Accordingly, PTE registration is allowed in Japan only for patents granted for inventions relating to pharmaceutical drugs or agrochemicals (the following parts of this article focus on pharmaceutical drugs, although they also apply to agrochemicals).

One characteristic of the PTE system in Japan is that patents the terms of which can be extended by PTE registration are not limited to those claiming an active ingredient, but include other related patents such as those claiming a pharmaceutical/agrochemical composition containing such an active ingredient and those claiming a process for producing such an active ingredient. Another characteristic is that the terms of two or more patent rights can be extended by PTE based on a single administrative disposition, and the term of a single patent right can be extended two or more times by PTE registrations based on two or more administrative dispositions. In other words, it is not necessary to choose one of two or more relevant administrative dispositions as a basis for PTE registration or to choose one of two or more relevant patent rights as a subject of PTE registration.

In order to obtain a PTE registration, the patentee has to file an application for which he seeks PTE registration (hereinafter, a PTE application) at the JPO within a designated period of time, together with evidence proving that there was a period during which the patented invention could not be worked due to it being necessary to obtain an administrative disposition (Article 67bis (67-2) of the Patent Law). The JPO Examiner then examines the PCT application and, if any of the registration requirements is not satisfied, issues a reason for rejection (Article 67ter (67-3), paragraph 1 of the Patent Law). Otherwise, the PTE is granted and registered by the JPO (Article 67ter, paragraphs 2 & 3 of the Patent Law), resulting in extension of the term of the patent right.

2. Background:

Two major issues of contention have arisen in relation to the PTE system based on administrative depositions (e.g., marketing approvals of pharmaceutical products): one relates to the JPO's examination guidelines for PTE applications (Article 67ter (67-3), paragraph 1, item 1 of the Patent Law); while the other relates to the effective scope of a patent right extended via PTE registration (Article 68bis (68-2) of the Patent Law).

The issue relating to the examination criteria for PTE applications centered on how to interpret Article 67ter (67-3), paragraph 1, item 1 of the Patent Law, which prescribes that a PTE application shall be rejected when "it is not deemed that obtaining a disposition designated by Cabinet Order recited in Article 67, paragraph 2 of the Patent Law was necessary for working the patented invention". This issue was recently settled via a series of rulings rendered by the Grand Panel of the IP High Court3 and accepted by the Supreme Court4, which led to the JPO revising its examination guidelines on April 1, 2016,5 in order to clarify how this article should be interpreted.

The issue relating to the effective scope of a patent right extended via PTE registration lies in how to interpret Article 68bis (68-2) of the Patent Law, which prescribes that a patent right the term of which is extended via PTE registration "shall not be effective against any act other than the working of the patented invention for the product which was the subject of the disposition designated by Cabinet Order recited in Article 67, paragraph 2 of the Patent Law that constituted the reason for the PTE registration (when the specific usage of the product is prescribed in the disposition, the product used specifically for that usage)". Specifically, there has been controversy over how the terms "product" and "usage" in this article should be interpreted. However, there are as yet no definitive criteria or court rulings issued as to the interpretation of this article.

Against this backdrop, the Grand Panel of the IP High Court rendered a side opinion as to the effective scope of a patent right extended via PTE registration, in its decisions mentioned above6. In this side opinion, the IP High Court ruled that "in light of the purpose of the PTE registration system and that of a patent infringement action, it is reasonable to understand that in the case of a patented invention relating to an ingredient of a medicine, a patent right whose duration was extended pursuant to Article 68bis (68-2) of the Patent Law shall be effective within the scope of working of the patented invention identified by 'ingredients (not limited to API)' as the 'product' and by 'effectiveness/efficacy'and 'dosage/regimen'as the 'usage'." This ruling, if interpreted strictly, could mean that the scope of a patent right extended via PTE registration would not be effective against an allegedly infringing medicinal product which is identical to the subject medicine of the deposition in active pharmaceutical ingredient (API), efficacy/effect, and dosage/regimen, but differs slightly from the subject of the deposition only in an ingredient other than the API (such as an excipient). Thus, this ruling could render the effective scope of an extended patent right unduly restrictive. As a result, many pharmaceutical companies, mainly innovators, have expressed strong concern regarding such restrictive claim construction.

To read this article in full, please click here.

Footnotes

1. The dispositions subject to this article are specifically prescribed in Article 2 of the Order for Enforcement of the Patent Law.

2. Renamed from the previous Pharmaceutical Affairs Law on November 14, 2014.

3. The decisions handed down by the grand panel of the IP High Court on May 30, 2014, (Cases Nos. 2013 (Gyo-Ke) 10195, etc.; suits rescinding trial decisions made by the JPO)

4. The decisions handed down by the third petty bench of the Supreme Court of Japan on November 17, 2015 (Cases Nos. 2014 (Gyo-Hi) 356, etc.; appeal cases against the IP High Court decisions mentioned in footnote 2 above).

5. The Examination Guidelines for Patent and Utility Model in Japan (last revised on April 1, 2016), "IX: Extension of Patent Term", Section 3.1.1, which prescribes that the Examiner shall deem that a disposition designated by Cabinet Order recited in Article 67, paragraph 2 of the Patent Law has been necessary to obtain for working of the patented invention and issue a reason for rejection under Article 67ter (67-3), paragraph 1, item 1 of the Patent Law either:

(i) when an act of manufacturing and distribution of drug products or an act of manufacturing and import of agricultural chemicals subject to the present disposition does not fall under an act of working of the patented invention pertaining to an application for registration of extension; or

(ii) in case an act of manufacturing and distribution of drug products or an act of manufacturing and import of agricultural chemicals subject to both the present disposition and the prior disposition falls under an act of working of the patented invention pertaining to an application for registration of extension, when manufacturing and distribution of drug products or manufacturing and import of agricultural chemicals subject to the prior disposition include those subject to the present disposition.

6. See footnote 2 above.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.